Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Publikáció
CD226⁺TIGIT⁺ MAIT cells exhibit an increased relative frequency and a checkpoint-enriched phenotype in Sjögren's disease.
2026. okt. 27.· Clinical rheumatology· PUBMED
Publikáció
Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR T-cell therapy) for relapsed or refractory LBCL: the CRC01-01 trial.
2026. okt. 22.· Blood· PUBMED
Publikáció
Phenotypic Landscape of Programmed Death and TIGIT/CD155/DNAM-1 Pathways in NK Cells in Ovarian Cancer.
2026. okt. 21.· Biomedicines· PUBMED
Publikáció
CTLA-4/PD-1, LAG-3, and TIGIT Inhibitors: Emerging Drug Targets and Combination Strategies in Hepatocellular Carcinoma.
2026. okt. 20.· Current cancer drug targets· PUBMED
Publikáció
Higher TIGIT expression in the intraperitoneal immune microenvironment is associated with shorter progression-free survival in patients with gastric cancer with peritoneal metastasis treated with intraperitoneal paclitaxel.
2026. okt. 16.· Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico· PUBMED
Publikáció
TNFα-driven epigenetic upregulation of TIGIT creates a targetable vulnerability in tumors.
2026. okt. 12.· Oncogene· PUBMED
Publikáció
TIGIT+ B cells: emerging immunoregulatory players in autoimmunity and transplantation tolerance with therapeutic potential.
2026. szept. 29.· Frontiers in immunology· PUBMED
Publikáció
TIGIT regulates CD8+T cell exhaustion via the PI3K/AKT-FOXO1-TOX axis in extrahepatic cholangiocarcinoma.
2026. szept. 29.· Clinical immunology (Orlando, Fla.)· PUBMED
Publikáció
Adjuvant anti-TIGIT plus anti-PD-1 in melanoma: A necessary failure that clarifies the path forward.
2026. szept. 28.· Translational oncology· PUBMED
Publikáció
Beyond PD-L1/PD-1: expression of PVR/TIGIT and TNFRSF14/BTLA axes in response to Helicobacter pylori and in gastric cancer lesions.
2026. szept. 22.· ImmunoHorizons· PUBMED
Publikáció
Corrigendum to "Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A challenge for clinical biomarker testing" [Neoplasia 38 (2023) 100884].
2026. szept. 21.· Neoplasia (New York, N.Y.)· PUBMED
Publikáció
Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia.
2026. szept. 17.· Oncoimmunology· PUBMED
Publikáció
TIGIT+ CD4+ T Cell Enrichment in Colorectal Liver Metastases Is Associated with Shorter Survival.
2026. szept. 15.· Cancers· PUBMED
Publikáció
TIGIT at a crossroads: lessons from SKYSCRAPER-03 in unresectable stage III NSCLC.
2026. szept. 11.· Annals of oncology : official journal of the European Society for Medical Oncology· PUBMED
Publikáció
The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer.
2026. aug. 20.· Frontiers in immunology· PUBMED
Publikáció
Pharmacological inhibition of LSD1 suppresses the CD155/TIGIT immune checkpoint axis and enhances NK cell-mediated cytotoxicity in colorectal cancer.
2026. aug. 11.· Bioorganic chemistry· PUBMED
Publikáció
The Right Key, the Wrong Lock: TIGIT Checkpoint Blockade and the Road to Precision Immunotherapy.
2026. aug. 7.· Pharmaceutics· PUBMED
Publikáció
Anti-TIGIT in PD-L1-High Advanced Non-Small Cell Lung Cancer: Insights From SKYSCRAPER-01 and the Path Forward.
2026. júl. 27.· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publikáció
Artemisinin liposomes regulates breast cancer metastasis and apoptosis through TIGIT/CD155 signal axis.
2026. júl. 27.· Apoptosis : an international journal on programmed cell death· PUBMED
Publikáció
Intratumoral TIGIT blockade augments antitumor responses and bypasses increased functionality of peripheral TIGIT+ NK cells in mouse and human models of bone and soft tissue sarcoma.
2026. júl. 22.· Journal for immunotherapy of cancer· PUBMED
Publikáció
AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic NSCLC With PD-L1 Expression of 50% or More.
2026. júl. 14.· Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer· PUBMED
Publikáció
Dual TIGIT and PD-1 blockade in immunotherapy-refractory hepatocellular carcinoma: a signal beyond resistance?
2026. júl. 1.· Hepatobiliary surgery and nutrition· PUBMED
Publikáció
Tumor lymph node metastasis chip reveals that the NECTIN3-TIGIT axis promotes melanoma metastasis by enhancing treg cell function and inducing CD8+ T cell exhaustion.
2026. jún. 25.· Cellular oncology (Dordrecht, Netherlands)· PUBMED
Publikáció
Comprehensive Bioinformatic Characterization of CD70, CD80, and TIGIT as Diagnostic, Prognostic, and Immune Biomarkers in Pan-Cancer.
2026. jún. 21.· Current issues in molecular biology· PUBMED
Publikáció
PD-1 and TIGIT coexpression enables selective enrichment of clonally expanded tumor-reactive CD8 T cells for melanoma TIL therapy.
2026. jún. 17.· Journal of translational medicine· PUBMED
Publikáció
No RFS benefit found from adding vibostolimab to pembrolizumab in patients with high-risk melanoma: Adding the anti-TIGIT antibody vibostolimab to adjuvant pembrolizumab failed to improve recurrence-free survival and increased toxicity.
2026. jún. 15.· Cancer· PUBMED
Publikáció
Beyond PD-1/PD-L1: Reprogramming the Gynecologic Tumor Microenvironment by Targeting TIGIT and Myeloid Suppression.
2026. jún. 14.· International journal of molecular sciences· PUBMED
Publikáció
Peripheral immune profiling identifies CD8⁺ TEMRA and CD4⁺ T TIGIT⁺ cells as independent prognostic markers for first-line immune checkpoint inhibitors in advanced non-small cell lung cancer.
2026. jún. 10.· Respiratory research· PUBMED
Publikáció
TIGIT expression dictates the immunosuppressive reprogramming of myeloid cells in glioblastoma.
2026. jún. 1.· Neuro-oncology· PUBMED
Publikáció
NK Cell Profiling: Expression of TIGIT and LAG3 as Immune Checkpoints in Advanced Endometriosis.
2026. jún. 1.· American journal of reproductive immunology (New York, N.Y. : 1989)· PUBMED